NeutriSci
(TSX VENTURE: $NU) (OTCQB: $NRXCF) Forms Cannabinoid Joint Venture With Lexaria
Bioscience (CSE: $LXX) (OTCQB: $LXRP)
VANCOUVER, BC - April 11, 2017
(Investorideas.com Newswire) NeutriSci International Inc. (the
"Company" or "NeutriSci") (TSX VENTURE: NU) (OTCQB: NRXCF)
(FRANKFURT: 1N9) and Lexaria Bioscience Corp. ("Lexaria") (CSE: LXX)
(OTCQB: LXRP) are pleased to announce finalization of the joint venture between
the companies to produce and commercialize a line of healthy, sugar-free,
edible cannabinoid sublingual tablets combining NeutriSci's proprietary
pterostilbene tablet form factor and Lexaria's patented technology.
The new company to be formed, Ambarii
Trade Corporation ("Ambarii"), is initially being funded and owned
equally by each of NeutriSci and Lexaria. NeutriSci and Lexaria are each
contributing its respective technology to Ambarii by way of a license, and will
split all profits derived from Ambarii operations on a 50/50 basis.
Ambarii will immediately work to
secure licensees in California, Colorado and Canada, to manufacture and sell
sublingual melt tablets containing THC and CBD. The products will also combine
the benefits of both NeutriSci's and Lexaria's existing technologies and
ingredient mixes. Initial manufacturing arrangements have been secured with a
licensed entity in California which will begin large scale test runs in May,
2017 with plans to manufacture and test a fully functioning THC and CBD version
of the product. In more developed legal markets such as California and
Colorado, cannabis edibles often comprise 33% - 55% market share of all legal
cannabis products, making high quality cannabis edibles vitally important to
the marketplace.
Ambarii will also enter the hemp oil
based market for sublingual melt products, which are not as highly regulated in
some jurisdictions as THC-based products. Distribution for these products will
be developed through NeutriSci's existing network of retail distributors as
well as other methods. Initial test production runs of the hemp oil variety of
pterostilbene-containing products have already achieved very positive human
focus group results, as previously announced.
Glen Rehman, President of NeutriSci
stated, "We are thrilled to officially partner with Lexaria. As we
continue our advanced discussions with some of Canada's leading medical
marijuana companies, this JV Agreement represents a giant leap forward for the
development, sale and manufacturing of cannabis edibles. Ambarii will deliver
an edible product that is not only highly effective, but also a healthy sugar
free alternative powered by pterostilbene. The Ambarii product line will be
world class, and will have high appeal to today's health conscious medicinal
and recreational users."
On Behalf of the Board of Directors
of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
President
NeutriSci International Inc.
Tel: (403) 264-6320
Email: grehman@neutrisci.com
Glen Rehman
President
NeutriSci International Inc.
Tel: (403) 264-6320
Email: grehman@neutrisci.com
Neither TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this
release.
This news release may include
forward-looking statements that are subject to risks and uncertainties. All
statements within, other than statements of historical fact, are to be
considered forward looking. Although the Company believes the expectations
expressed in such forward-looking statements are based on reasonable
assumptions, such statements are not guarantees of future performance and
actual results or developments may differ materially from those in
forward-looking statements. Factors that could cause actual results to differ
materially from those in forward-looking statements include market prices,
exploitation and exploration successes, continued availability of capital and
financing, and general economic, market or business conditions. There can be no
assurances that such statements will prove accurate and, therefore, readers are
advised to rely on their own evaluation of such uncertainties. We do not assume
any obligation to update any forward-looking statements except as required
under the applicable laws.
About NeutriSci
International Inc.
NeutriSci specializes in the
innovation, production and formulation of nutraceutical products. Established
in 2009, NeutriSci is currently focussed on building sustainable sales models
with Convenience, Chain Drug, and Mass Market and Supermarket retailers for
neuenergy®, the Company's natural energy and focus supplement that has at its
core, the beneficial effects of blueberries.
Neuenergy® contains a unique patented
combination of blueberries (pterostilbene) and naturally derived caffeine, and
is a revolutionary energy tab designed to deliver enhanced focus and mental
clarity with no sugar, no calories and no crash associated with typical energy
products. To find out more about neuenergy®, please visit www.getneuenergy.com.
About Lexaria:
Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company's lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while
also masking taste. This technology promotes healthy ingestion methods, lower
overall dosing and higher effectiveness in active molecule delivery. The
Company's technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules.
Statements in this press release have
not been evaluated by the Food and Drug Administration. Products or ingredients
are not intended to diagnose, treat, cure or prevent any disease.
Contact:
Glen Rehman
President
NeutriSci International Inc.
Tel: (403) 264-6320
Email: grehman@neutrisci.com
President
NeutriSci International Inc.
Tel: (403) 264-6320
Email: grehman@neutrisci.com
Watch the 420
Cannabis Investor video
More Info:
This news is published on the
Investorideas.com Newswire - a global digital news source for investors and
business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news,
articles and equity research as well as creates original content, including
video, interviews and articles. Original content created by investorideas is
protected by copyright laws other than syndication rights. Our site does not
make recommendations for purchases or sale of stocks, services or products.
Nothing on our sites should be construed as an offer or solicitation to buy or
sell products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info
regarding BC Residents and global Investors: Effective September 15 2008 - all
BC investors should review all OTC and Pink sheet listed companies for
adherence in new disclosure filings and filing appropriate documents with
Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.
Global investors must adhere to regulations of each country.
No comments:
Post a Comment